History Lifitegrast was initially designed and developed by SARcode Bioscience which was acquired by Shire in 2013, who submitted a new drug application to the US Food and Drug Administration (FDA) in March 2015. The FDA granted Shire a priority review a month later, and requested additional clinical data, which were supplied in January 2016; approval was granted on 11 July 2016.Drugs.com: Xiidra (lifitegrast) FDA Approval History Lifitegrast was approved by Health Canada in January 2018, and available in Canadian pharmacies as of March 2018. Shire has been acquired by Takeda Pharmaceutical Company in late 2018. In May 2019 Novartis has reached an agreement to purchase the assets associated with lifitegrast . Novartis will pay Takeda an upfront payment of $3.4 billion, while the latter drugmaker is eligible for milestone payments of as much as $1.9 billion. Novartis noted that the drug amassed approximately $400 million in revenue in 2018.
History Lifitegrast was initially designed and developed by SARcode Bioscience which was acquired by Shire in 2013, which submitted a new drug application to the US Food and Drug Administration (FDA) in March 2015. The FDA granted Shire a priority review a month later, and requested additional clinical data, which were supplied in January 2016; approval was granted on 11 July 2016.Drugs.com: Xiidra (lifitegrast) FDA Approval History Lifitegrast was approved by Health Canada in January 2018, and available in Canadian pharmacies as of March 2018. Shire was acquired by Takeda Pharmaceutical Company in late 2018. In May 2019 Novartis reached an agreement to purchase the assets associated with Lifitegrast . Novartis will pay Takeda an upfront payment of $3.4 billion, while the latter drugmaker is eligible for milestone payments of as much as $1.9 billion. Novartis noted that the drug amassed approximately $400 million in revenue in 2018.
R
who
which
R
has been
was
D
has
R
lifitegrast
Lifitegrast